As policy makers try to address unsustainable prices for biologic drugs, concerns about the fledgling US market for biosimilars have come to the forefront. Some experts have even suggested abandoning biosimilars in favor of more heavy-handed mechanisms to lower the prices of biologics. We agree that there are unique barriers to biosimilar competition. Giving up on the biosimilars market…
First-in-class drugs can be highly innovative because of their novel mechanisms of action, but they also carry uncertainty in the absence of clinical experience. To…
Recent policy directives from the White House seek to compel actions that are contrary to widely accepted standards of ethical public health practice.
President Trump campaigned on leaving the issue of abortion up to state policymakers. However, his administration has already prioritized federal policy changes that have or…
The current regulatory environment is marked by change and uncertainty. Without stability, affinity plans—still in their early stages of growth and positioned around meeting the…
The New York Giants have hired Moelis & Co. to explore the potential sale of up to 10 percent of the club, a deal that…
The potential of AI tools to mitigate clinician burnout could remain untapped if we fail to prioritize the clinician experience.
Private equity (PE) acquisitions of health care providers are often framed as a monolithic intervention, but firms’ strategies for generating returns for investors may vary.…
Health Affairs’ Jeff Byers welcomes Kinika Young of The Leukemia & Lymphoma Society to the program to discuss a recent final rule/advisory issued by the…
Health Affairs’ Jeff Byers welcomes Kinika Young of The Leukemia & Lymphoma Society to the program to discuss a recent final rule/advisory issued by the…
This article summarizes the provisions of the final 2026 HHS Notice of Benefit Payment Parameters related to the individual and small group market risk adjustment…
